Non-small cell lung cancer market to hit $26bn by 2025
pharmafile | November 24, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GlobalData, non-small cell lung cancer
New research from GlobalData has indicated that the non-small cell lung cancer (NSCLC) market will rise in value by over 300% from $6.21 billion in 2015 to $26.71 billion in 2025 across the eight major markets (US, France, Germany, Italy, Spain, the UK, Japan and China); a 15.7% compound annual growth rate.
According to the data, the projections will be driven by rises in disease incidences, the value and prevalence of immune-oncology therapies. The emergence of new targeted therapies for areas of unmet need with also be a significant factor, as will the development of PD-1 checkpoint inhibitors as a combination treatment, as utilised by BMS, Roche and Merck.
“In 2015, the NSCLC space was largely dominated by generic chemotherapy and targeted therapies, which accounted for around 94% of the market, while immuno-oncology sales accounted for just 6%,” GlobalData oncology analyst Cai Xuan explained. “In 2025, that trend will be reversed, with 65% of the total NSCLC market going to immuno-oncology therapies, and the remaining 35% being split between chemotherapy and targeted agents.
“A major trend in corporate strategy is the pairing of programmed cell death protein 1 (PD-1) checkpoint inhibitors with other agents,” he continued. “In the crowded PD-1 space, as drugs with identical mechanisms of action are launched, players are looking for ways to boost efficacy in hopes of differentiating their product from that of their competitors.
“In addition to novel therapies, companies are also developing second- and third-generation targeted therapies to provide better options for patients with actionable mutations. GlobalData expects these next-generation targeted therapies to take significant patient share away from their predecessors.”
Matt Fellows
Related Content
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy …
Combination first-in-line treatment approved for patients with non-small cell lung cancer
Johnson & Johnson Innovative Medicine have announced that the European Commission (EC) has approved a …
